stem cells

Here's Why Athersys Is Soaring Today
Here's Why Athersys Is Soaring Today
Motley Fool
Athersys
Japan
clinical trials
stem cells
MultiStem
ARDS
Flag link:
Mesoblast poised to file cell therapy for GVHD in US
Mesoblast poised to file cell therapy for GVHD in US
Pharmaforum
Mesoblast
stem cells
graft vs host disease
FDA
remestemcel-L
Flag link:
Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead
Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead
Endpoints
CAR-T
Gilead Sciences
UCLA
stem cells
Flag link:
Korean biotechs snatch U.S. stem cell manufacturing facility
Korean biotechs snatch U.S. stem cell manufacturing facility
Fierce Pharma
Korea
stem cells
Flag link:
Daiichi Sankyo takes option on diabetes stem cell start-up
Daiichi Sankyo takes option on diabetes stem cell start-up
Pharmaforum
Daiichi Sankyo
stem cells
Tokyo Institute of Technology
type 1 diabetes
OiDE BetaRevive
Flag link:
How Miniature Human Hearts Will Revolutionize Drug Testing
How Miniature Human Hearts Will Revolutionize Drug Testing
Forbes
drug safety
stem cells
Flag link:
ViaCyte Raises $80M to Prep for the Clinic Now, Perhaps an IPO Later
ViaCyte Raises $80M to Prep for the Clinic Now, Perhaps an IPO Later
Xconomy
ViaCyte
stem cells
diabetes
IPOs
clinical trials
Flag link:
Mesoblast defends stem cell therapy for heart failure after trial miss
Mesoblast defends stem cell therapy for heart failure after trial miss
Fierce Biotech
Mesoblast
stem cells
clinical trials
heart failure
Flag link:
Magenta stem cell transplant drug seems to work, but is it safe?
Magenta stem cell transplant drug seems to work, but is it safe?
Fierce Biotech
Magenta Therapeutics
MGTA-456
clinical trials
stem cells
Flag link:
NIH pauses stem cell trial after Brigham calls to retract 'fabricated' foundational research
NIH pauses stem cell trial after Brigham calls to retract 'fabricated' foundational research
BioCentury
NIH
stem cells
Brigham and Women's
Flag link:
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
CP Wire
Omeros
OMS721
stem cells
thrombotic microangiopathy
Flag link:
Harvard and the Brigham call for more than 30 retractions of cardiac stem cell research
Harvard and the Brigham call for more than 30 retractions of cardiac stem cell research
Stat
Harvard
Brigham and Women's
medical journals
stem cells
Flag link:
Novo to create California stem cell therapy manufacturing site
Novo to create California stem cell therapy manufacturing site
Pharmaforum
Novo Nordisk
stem cells
drug manufacturing
California
Flag link:
CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy
CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy
Xconomy
ViaCyte
stem cells
diabetes
CRISPR Therapeutics
Flag link:
Samumed, a $12 billion startup that wants to cure baldness and smooth out your wrinkles, just raised even more funding as it plots an IPO
Samumed, a $12 billion startup that wants to cure baldness and smooth out your wrinkles, just raised even more funding as it plots an IPO
Business Insider
Samumed
baldness
wrinkle treatment
IPOs
aesthetics
stem cells
Flag link:
Cellect, denovoMATRIX start stem cell research project
Cellect, denovoMATRIX start stem cell research project
Fierce Biotech
Cellect Biotechnology
TU Dresden
drug development
stem cells
denovoMATRIX
Flag link:
FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study
FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study
Xconomy
sickle cell disease
FDA
Vertex Pharmaceuticals
CRISPR Therapeutics
CTX001
stem cells
Flag link:
Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies
Novo Nordisk steps up interest in diabetes, Parkinson’s stem cell therapies
Fierce Biotech
Novo Nordisk
type 1 diabetes
stem cells
Flag link:
Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations
Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations
Endpoints
Novo Nordisk
type 1 diabetes
stem cells
Biolamina
Flag link:
Cellular Biomedicine Group to Release 48-week Data from Phase I Clinical Trial for Promising Stem Cell Therapy AlloJoin for Knee Osteoarthritis
Cellular Biomedicine Group to Release 48-week Data from Phase I Clinical Trial for Promising Stem Cell Therapy AlloJoin for Knee Osteoarthritis
CP Wire
Cellular Biomedicine
Allojoin
stem cells
osteoarthritis of the knee
Flag link:

Pages